Vertex Pharmaceuticals (VRTX) Reports ALYFTREK Child Data, Is The Stock Still Undervalued?

Vertex Pharmaceuticals (VRTX) drew fresh attention after releasing interim data on its ALYFTREK regimen in very young children with cystic fibrosis, suggesting some could stop pancreatic enzyme replacement therapy once considered lifelong.

Vertex Pharmaceuticals has been on a steady upward path over the past year, with the share price gaining 10.53% year to date and a 1-year total shareholder return of 19.90%, even as the stock eased 1.77% over the last session, following the ALYFTREK data release and North American Cystic Fibrosis Conference presentations.

Scan how Vertex Pharmaceuticals compares with other specialist drug makers that are contributing to rare disease treatment advances by reviewing the hand picked 20 high quality undiscovered gems in this space.

Bulls see Vertex Pharmaceuticals as a rare disease powerhouse with fresh ALYFTREK data to back the story. Bears point to a rich share price. Which case does the current valuation support next?

Most Popular Narrative: 12.5% Undervalued

On the most followed view, Vertex Pharmaceuticals screens as undervalued, with a fair value of $571.39 against a last close of $499.74. This anchors the current debate around whether the ALYFTREK data is already reflected in the price.

The acquisition of Crinetics for about US$10b in cash, which adds the approved oral acromegaly therapy Palsonify and the Phase III ACTH receptor antagonist atumelnant in congenital adrenal hyperplasia and Cushing’s, is expected by management to reach more than US$5b in combined peak annual sales and to be accretive to non GAAP operating income by 2029. This can affect both revenue growth and net margins once integration and launch investments are absorbed.

See why 139 investors see Vertex Pharmaceuticals as 13% undervalued.

Result: Fair Value of $571.39 (UNDERVALUED)

Still, the narrative around Vertex Pharmaceuticals can break if cystic fibrosis pricing or volumes weaken, or if the Crinetics acquisition underdelivers on expected economics.

Find out about the key risks to this Vertex Pharmaceuticals narrative.

Next Steps

If the mix of optimism and caution around Vertex Pharmaceuticals feels finely balanced, review the underlying numbers yourself and evaluate the bullish angles more closely. Start with the 3 key rewards.

Looking for more investment ideas beyond Vertex Pharmaceuticals?

Do not stop with one opportunity. Use the Simply Wall St screener to surface fresh angles and keep your watchlist sharp.

• Pressure test your value thesis by scanning a focused set of potentially mispriced businesses through the 33 high quality undervalued stocks.
• Strengthen your downside protection by reviewing companies that pass a strict balance sheet health check using the list of solid balance sheet and fundamentals (25 results).
• Hunt for early stage opportunities with stronger fundamentals than typical micro caps by checking the 13 elite penny stocks with strong financials.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com